CA-GLOBALLOGIC
8.4.2024 14:38:30 CEST | Business Wire | Press release
GlobalLogic, a Hitachi group company, today announced a first-of-its-kind Platform-of-Platforms architecture designed to support deployment of enterprise-grade artificial intelligence (AI). GlobalLogic has designed the architecture to address the critical challenges every enterprise must overcome when operationalizing AI and generative AI (GenAI) at scale.
To realize the potential that AI promises, enterprises must address data privacy and security requirements, prevent intellectual property (IP) leakage and manage legal risks. They also need to identify an approach that allows for technical agility as new models, platforms and other innovations take shape. At the same time, leaders must manage organizational change and find effective strategies for controlling costs and driving return on AI/GenAI investments.
With over a decade of experience in delivering and deploying AI in software products and enterprise platforms, GlobalLogic offers a unique perspective on the design, data and engineering challenges of enterprise-grade, production-ready AI and GenAI. Created in partnership with leading hyperscalers and leveraging their foundational GenAI capabilities, GlobalLogic’s architecture is the first of its kind for unifying and industrializing enterprise-grade AI and GenAI solutions.
GlobalLogic identifies responsibility, reliability and reusability as key to enterprise-grade AI
“As companies work to move from AI and GenAI prototypes to enterprise-scale deployments, it has become clear that using this technology requires far more than sending prompts to a large language model (LLM),” said Sumit Sood, COO and Head of Engineering, GlobalLogic. “We have been helping enterprises adopt GenAI since 2021 and ‘traditional’ AI for much longer, often in life-critical situations. We understand what needs to be done to ensure responsibility, reliability and reusability in AI platforms.”
Sood explains that the responsibility tenet focuses on the goal of offering responses that are accurate, lawful and in compliance with security and governance requirements. The reliability tenet requires mechanisms for correcting model drift, hallucinations and security threats over time. Finally, the reusability tenet is crucial to implementing common data ingestion, preparation and model training and shared consumption mechanisms – which help contain costs and mitigate risk by preventing duplicative work.
GlobalLogic’s AI Platform-of-Platforms architecture addresses critical needs related to observability, security, governance and consumption. It makes it possible to integrate best-of-breed models, algorithms and solutions whether deployed in the cloud or on premises. It also includes accelerators for rapidly deploying some of the most sought-after use cases, including customer support and operations, software development and legacy migration, and enterprise knowledge management.
“The GenAI landscape is highly dynamic,” Sood said. “In an environment where the ‘best’ technology can change month to month or even week to week, GlobalLogic’s Platform-of-Platforms approach lets our clients pick the winners to deliver the best enterprise-class GenAI to support their business outcomes.”
To learn more about GlobalLogic’s AI solutions and advisory capabilities, visit www.globallogic.com/services/offerings/generative-ai/.
ABOUT GLOBALLOGIC
GlobalLogic (www.globallogic.com) is a leader in digital engineering. We help brands across the globe design and build innovative products, platforms, and digital experiences for the modern world. By integrating experience design, complex engineering, and data expertise—we help our clients imagine what’s possible and accelerate their transition into tomorrow’s digital businesses. Headquartered in Silicon Valley, GlobalLogic operates design studios and engineering centers around the world, extending our deep expertise to customers in the automotive, communications, financial services, healthcare and life sciences, manufacturing, media and entertainment, semiconductor, and technology industries. GlobalLogic is a Hitachi Group Company operating under Hitachi, Ltd. (TSE: 6501), which contributes to a sustainable society with a higher quality of life by driving innovation through data and technology as the Social Innovation Business.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240408417447/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
FDA Issues Modified Risk Tobacco Product Orders for 20 ZYN Nicotine Pouch Products30.6.2026 18:19:00 CEST | Press release
FDA’s decision makes ZYN the first nicotine pouch product to receive MRTP orders authorizing reduced-risk claims versus cigarettes Philip Morris International Inc. (PMI) (NYSE: PM) today announced that the U.S. Food and Drug Administration (FDA) issued Modified Risk Tobacco Product (MRTP) orders for 20 variants of ZYN nicotine pouch products. These are the first MRTP orders granted for nicotine pouches, allowing PMI U.S. to market the following claim for the authorized ZYN products: “Using ZYN instead of cigarettes puts you at a lower risk of mouth cancer, heart disease, lung cancer, stroke, emphysema, and chronic bronchitis.” “FDA’s decision is an important moment for the more than 45 million legal-age nicotine consumers in America,” saidStacey Kennedy, PMI U.S. CEO. “Today’s news ensures these adultshave access to accurate, science-based information, including FDA-authorized evidence that switching from cigarettes to ZYN reduces the risk of smoking-related diseases like heart disease
Caidya Announces Strategic Combination with Simbec-Orion Bridging Early Scientific Insight and Global Clinical Execution30.6.2026 17:00:00 CEST | Press release
Caidya today announced a strategic combination with Simbec-Orion designed to close the divide between early scientific insight and global clinical execution. The combination of Caidya and Simbec-Orion creates a differentiated specialty clinical CRO platform that enables programs to scale, maintaining focus, speed, and accountability. The strategic combination brings together complementary strengths to create a more complete development partner for innovative biopharma companies. With established operations across Europe, the Americas, APAC, and China, the combined organization provides meaningful expertise and execution capabilities in the regions that matter most. Simbec-Orion brings early-phase clinical pharmacology capabilities alongside deep therapeutic expertise for later stage complex oncology and rare disease trials, helping sponsors shape critical decisions early in the development lifecycle. Together, the organizations strengthen their ability to support complex, cross-border
Archer® Proves Purpose-Built AI Beats General-Purpose LLMs on Regulatory Change Management: 95% Verified Accuracy, 80x Faster, 92% Lower Cost30.6.2026 16:13:00 CEST | Press release
In a head-to-head benchmark, a leading general-purpose LLM was confidently wrong 35% of the time on regulatory dates. Archer Evolv™ shipped zero errors. For enterprises deploying AI in compliance, a wrong date is a missed deadline. The more dangerous failure is a wrong answer the model returns with high confidence, one that flows silently into a compliance calendar and is only discovered after the window has passed. Archer® today released results showing purpose-built AI beats a general-purpose large language model (LLM) on regulatory work, and it’s not close. This head-to-head test compared Archer’s purpose-built, vertical-specific AI and proprietary data sets against a leading general-purpose LLM, on a core compliance task: determining the publication, effective and comment-close dates of regulatory documents across six jurisdictions. General-purpose models are a genuine breakthrough, and this is no referendum on their quality. The question Archer set out to answer is narrower and mo
Altasciences Supports Key Development Milestone for Steel Therapeutics’ Lead Therapeutic Candidate, Fizurex™30.6.2026 16:08:00 CEST | Press release
Altasciences, a leading drug development organization, today announced a significant milestone in the development of Steel Therapeutics, Inc.’s pivotal toxicology study for its lead product candidate, Fizurex™, for the treatment of anal fissures. The successful completion of the study plays a significant role in the advancement of Fizurex™ toward first-in-human trials. The GLP-compliant study demonstrated a favorable safety profile, which has advanced Steel Therapeutics' plans to submit an Investigational New Drug (IND) application for Fizurex™ to the FDA in Q3 2026. Fizurex™, a patent-pending, single-use topical wipe, was designed to provide a standardized, accessible treatment option for a painful and often undertreated medical condition. The product builds on years of use through compounding pharmacy prescriptions and is now advancing toward clinical development and regulatory review. "We are proud to have supported Steel Therapeutics with the generation of the high-quality safety d
Interactive Brokers Expands Access to Korean Equities with Launch of Nextrade ATS30.6.2026 16:00:00 CEST | Press release
IB SmartRouting℠ Routes Orders to the Best Available Price Between KRX and Nextrade Interactive Brokers (Nasdaq: IBKR), an automated global broker, today announced the launch of select Korean equities through Nextrade, South Korea's first Alternative Trading System (ATS). The addition of Nextrade builds on Interactive Brokers' earlier launch of the Korea Exchange (KRX), through which it became the first major US-based broker to provide global investors with direct access to Korean equities. Clients trading on Nextrade benefit from significantly extended trading hours and access to additional liquidity. Interactive Brokers has enabled IB SmartRouting℠ across both the Korea Exchange (KRX) and Nextrade, automatically routing orders to the venue offering the best price. This helps clients achieve best execution while providing greater flexibility and more opportunities to participate in one of Asia's most dynamic equity markets. Korea's equity market ranks among the top global exchanges by
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
